Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From an internist's perspective, doxycycline hyclate is a great drug. Probably my favorite antibiotic overall. I prescribe a lot of doxy. Excellent respiratory coverage, including pneumonia and sinusitis. Excellent for skin. Allergies are uncommon, and it is well-tolerated from a G.I. perspective. It is also not frequently associated with antibiotic-associated opportunistic infections, like clostridium difficile diarrhea, which is a real killer. But what really sets doxy apart from other classes, though, is that it nicely covers MRSA (methicillin-resistant Staph), which used to be mainly a hospital-acquired bug but now has become ubiquitous in the community. In my experience, if I treat skin without covering MRSA, I often regret it and have to add it on later, so I usually try to start from the beginning with an antibiotic that will do the job. The problem for us all is that there aren't many antibiotics that cover MRSA, and certainly not oral drugs as efficacious and well-tolerated as doxy. While it seems like many of Elite's generic drugs are relics from the past, doxycycline hyclate is an antibiotic for now and for the future.
FYI: A parody of a parody earns zero satire points.
Yes, this is going to explode any day. Which is why I will continue to discuss matters about Elite Pharmaceuticals to the board. I will spend my time discussing $ELTP even though I say this is going to explode any day for the past nine years. I will talk about $ELTP every day for the next 2 years even though I say this is going to explode any day for the past nine years. ELTP. I will refrain from mentioning how the share count is related to the share price. I will constantly repost how the company's current assets in house almost equate the market cap even though this is already well-known to the market. I will pretend there is a secret asset that the market doesn't know about even though it's been in the quarterly reports for years and that it is extremely awesome how the company has lost $100 million but I'm the only guy smart enough to know it.
/s
Wrong.
Submitted
Question for CC:
During the last several calls, the CEO has discussed using "our technology" for an ADF version of CNS stimulants. He said our technology is effective on all pleasure centers and "even works on alcohol", which suggests he is referring to naltrexone drug effects. Is the CEO considering the development of a naltrexone-based antagonist ADF for CNS stimulants? If so, what is the evidence that naltrexone can be used as an antagonist molecule for CNS stimulants? Are there are any studies that can be cited that suggest this would be effective? Are there any other drugs or experimental molecules that he is aware of that have shown this to be possible? What are they?